Search
for

    Glossary Imatinib

    targets specific enzymes to treat certain cancers like CML

    Imatinib, also known as Gleevec, is a targeted cancer therapy drug used primarily to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It works by inhibiting specific tyrosine kinases, which are enzymes that promote the growth of cancer cells, thereby slowing or stopping the progression of the disease.

    Sort by

    Research 30 of 206

    1. Hair graying and loss induced by imatinib mesylate The Journal of Dermatology · 2013 · 7 citations
    2. Imatinib-induced classical lichen planopilaris in blaschko-linear distribution leading to cicatricial alopecia Indian Dermatology Online Journal · 2021 · 2 citations
    3. Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib Journal of clinical medicine · 2023
    4. Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects Current drug metabolism · 2009 · 508 citations
    5. The PDGF/PDGFR pathway as a drug target Molecular Aspects of Medicine · 2017 · 182 citations
    6. Cutaneous Scarring: Basic Science, Current Treatments, and Future Directions Advances in wound care · 2016 · 178 citations
    7. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas British Journal of Dermatology · 2003 · 68 citations
    8. Tyrosine kinase inhibition and grey hair The Lancet · 2003 · 59 citations
    9. Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia Journal of the American Academy of Dermatology · 2013 · 25 citations
    10. Skin toxicity of anti‐cancer therapy Journal der Deutschen Dermatologischen Gesellschaft · 2008 · 19 citations
    11. Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia JAMA Dermatology · 2013 · 9 citations
    12. Author reply Cancer · 2004 · 1 citations
    13. Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique 2011
    14. Skin manifestations of chronic kidney disease Actas Dermo-Sifiliográficas · 2015
    15. Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods Pharmaceuticals · 2021 · 42 citations
    16. Nilotinib-Induced Keratosis Pilaris Case Reports in Dermatology · 2016 · 19 citations
    17. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta ophthalmologica · 2012 · 54 citations
    18. Targeted therapy in melanoma Clinics in Dermatology · 2013 · 21 citations
    19. Updates from the British Association of Dermatologists 91st Annual Meeting, 5-7 July 2011, London, U.K. British Journal of Dermatology · 2012 · 1 citations
    20. Solitary, subcutaneous, fixed, firm, and fast-growing nodule JAAD case reports · 2022
    21. Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical <i>in silico/in vitro</i> screening methods bioRxiv (Cold Spring Harbor Laboratory) · 2020
    22. Research progress on drug-induced gynecomastia 药物不良反应杂志 · 2015
    23. Cutaneous Drug Reaction Case Reports American Journal of Clinical Dermatology · 2003
    24. Multiple skin cancers in a patient within 1 year of allogeneic haematopoietic cell transplant for chronic lymphocytic leukaemia Clinical and Experimental Dermatology · 2015 · 1 citations
    25. Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma Clinical cancer research · 2004 · 234 citations
    26. Medication-Induced Repigmentation of Gray Hair: A Systematic Review Skin appendage disorders · 2019 · 28 citations
    27. Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis JAAD Case Reports · 2018 · 12 citations
    28. Hair Manifestations of Systemic Disease Current Problems in Pediatric and Adolescent Health Care · 2012 · 10 citations
    29. Hair Re-Pigmentation After Nilotinib Turkish Journal of Hematology · 2025
    30. P62: An increase in Breslow thickness: coronavirus or coincidence? British Journal of Dermatology · 2021